02
MAY
2016
NW Bio Announces Operations Updates
Comments : Off
New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance BETHESDA, MD, May 2, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance. The Company has reached... Read More